<DOC>
	<DOCNO>NCT02496052</DOCNO>
	<brief_summary>To estimate efficacy safety dry biological amnion graft hysteroscopic lysis intrauterine adhesion .</brief_summary>
	<brief_title>The Efficacy Safety Dried Biological Amnion Graft Patients With Intrauterine Adhesions</brief_title>
	<detailed_description>Allocation : Randomized Endpoint Classification : Safety/Efficacy Study Intervention Model : Parallel Assignment Masking : Single Blind ( Subject ) Primary Purpose : Prevention</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>age 2040 years； previously diagnostic hysteroscopy confirm adhesion score &gt; 5， accord American Fertility Society （AFS）classification IUA； complain menstruation disorder reproductive dysfunction； inform consent . premature menopause , presence intrauterine lesion ( e.g . polyp , myoma , septum ) , presence severe intercurrent illness ( e.g . systemic disease , coagulative disorder , severe kidney liver disease ) , adhesion limit low uterine cavity cervical canal .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>amnion graft</keyword>
	<keyword>New biological barrier system</keyword>
</DOC>